Brief: Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
10/03/2025 21:36
March 10 (Reuters) - Kodiak Sciences Inc KOD.O: KODIAK SCIENCES COMPLETES ENROLLMENT IN SECOND REGISTRATIONAL TRIAL OF TARCOCIMAB IN PATIENTS WITH DIABETIC RETINOPATHY Source text: ID:nPn4nWK0la Further company coverage: KOD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kodiak Sciences
See all newsBrief: Kodiak Sciences Inc. Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX